Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
17.81B
Market cap17.81B
Price-Earnings ratio
19.55
Price-Earnings ratio19.55
Dividend yield
Dividend yield
Average volume
484.33K
Average volume484.33K
High today
$274.10
High today$274.10
Low today
$265.87
Low today$265.87
Open price
$267.00
Open price$267.00
Volume
1.02M
Volume1.02M
52 Week high
$282.15
52 Week high$282.15
52 Week low
$186.05
52 Week low$186.05

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $272.89, giving the company a market capitalization of 17.81B. It carries a P/E multiple of 19.55.

On 2026-09-03, Ascendis Pharma A/S(ASND) stock moved within a range of $265.87 to $274.10. With shares now at $272.89, the stock is trading +2.6% above its intraday low and -0.4% below the session's peak.

Trading volume for Ascendis Pharma A/S(ASND) stock has reached 1.02M, versus its average volume of 484.33K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

ASND News

TipRanks 14m
Ascendis Pharma Director’s Bold Stock Move Grabs Investor Attention

New insider activity at Ascendis Pharma ( (ASND) ) has taken place on September 3, 2026. Ascendis Pharma director Lars Holtug has recently trimmed his holdings...

TipRanks 2d
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer

Oppenheimer raised the firm’s price target on Ascendis Pharma to $312 from $304 and keeps an Outperform rating on the shares. The firm has revised its Ascendis...

Investing.com 2d
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com

...

Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

Simply Wall St 3d
Ascendis Pharma Clears Yuviwel Patent Fight With Global Licensing Deal

Ascendis Pharma (NasdaqGS:ASND) and BioMarin Pharmaceutical reached a global settlement and licensing agreement resolving all patent disputes over Yuviwel and n...

Ascendis Pharma Clears Yuviwel Patent Fight With Global Licensing Deal
TipRanks 3d
Ascendis Pharma Strikes Global Settlement and Licensing Deal With BioMarin Over YUVIWEL

Ascendis Pharma ( (ASND) ) has shared an announcement. On August 31, 2026, Ascendis Pharma announced a binding term sheet for a global settlement and license a...

TipRanks 4d
Ascendis Pharma: ITC Risk Seen as Manageable, YUVIWEL Traction Supports Unchanged $345 Price Target and Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Ascendis Pharma today and set a price target of $345.00. Mitchell Kapoor has given his Buy ra...

TipRanks 4d
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

BioMarin (BMRN) announced that it has entered into binding terms with Ascendis Pharma (ASND), resolving the patent and ancillary disputes pending globally, incl...

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.